Since the NRF2 pathway modulates several genes involved in glucose and lipid metabolism, many NRF2 activators have been tested in order to uncover the therapeutic effects of NRF2 on obesity and its comorbidities. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.